Insulet Corp (FRA:GOV)
€ 172 1.6 (0.94%) Market Cap: 12.07 Bil Enterprise Value: 12.67 Bil PE Ratio: 56.75 PB Ratio: 16.58 GF Score: 82/100

Insulet Corp at Raymond James Institutional Investors Conference Transcript

Mar 03, 2020 / 04:00PM GMT
Release Date Price: €161 (+1.26%)
Jayson Tyler Bedford
Raymond James & Associates, Inc., Research Division - Senior Medical Supplies and Devices Analyst

All right. Good morning. I think we'll get started. Welcome to the 41st Annual Raymond James Institutional Investors Conference. My name is Jayson Bedford. I'm one of the medical device analyst here at Ray J. It's our privilege to have with us the senior management team from Insulet. They've been a loyal participant in this conference for many years.

With us, we have Head of Investor Relations and Corporate Communications, Deb Gordon; CFO, Wayde McMillan; and the CEO, Shacey Petrovic. So I will hand it off to Shacey, and we'll have the breakout downstairs in, I think, Amarante 5.

Shacey Petrovic
Insulet Corporation - President, CEO & Director

Thanks, Jason. So I might be double mic-ed here. So hopefully, I'm okay. But it's great to be with you all this morning to share a bit about Insulet Corporation. Our mission at Insulet is to improve the lives of people living with diabetes. And we do that through our novel Omnipod

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot